These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16395104)

  • 1. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children.
    Puthanakit T; Oberdorfer P; Akarathum N; Wannarit P; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2006 Jan; 25(1):53-8. PubMed ID: 16395104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children after initiation of antiretroviral therapy.
    Gkentzi D; Tebruegge M; Tudor-Williams G; Walters S; Lyall H; Sharland M; Doerholt K
    Pediatr Infect Dis J; 2014 Sep; 33(9):953-8. PubMed ID: 24618936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.
    Shelburne SA; Visnegarwala F; Darcourt J; Graviss EA; Giordano TP; White AC; Hamill RJ
    AIDS; 2005 Mar; 19(4):399-406. PubMed ID: 15750393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.
    Levin MJ; Anderson JP; Seage GR; Williams PL;
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):182-91. PubMed ID: 19131890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.
    Tangsinmankong N; Kamchaisatian W; Lujan-Zilbermann J; Brown CL; Sleasman JW; Emmanuel PJ
    J Allergy Clin Immunol; 2004 Apr; 113(4):742-6. PubMed ID: 15100682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution inflammatory syndrome in adult human immunodeficiency virus-infected patients in Thailand.
    Aramaki M; Silachamroon U; Desakorn V; Maek-A-nantawat W; Waiwaruwut J; Jutiwarakun K; Kim JH; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):138-45. PubMed ID: 20578492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru.
    Wang ME; Castillo ME; Montano SM; Zunt JR
    Pediatr Infect Dis J; 2009 Oct; 28(10):900-3. PubMed ID: 19687769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand.
    Puthanakit T; Aurpibul L; Oberdorfer P; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2007 Oct; 26(10):953-6. PubMed ID: 17901804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.
    Weinberg A; Wiznia AA; LaFleur BJ; Shah S; Levin MJ
    J Infect Dis; 2004 Jul; 190(2):267-70. PubMed ID: 15216460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous cryptococcosis as a rare manifestation of the immune reconstitution syndrome in an HIV-1-infected patient.
    Gasiorowski J; Knysz B; Szetela B; Gładysz A
    Postepy Hig Med Dosw (Online); 2008 Jan; 62():1-3. PubMed ID: 18202595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.
    Puthanakit T; Aurpibul L; Oberdorfer P; Akarathum N; Kanjananit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Feb; 44(4):599-604. PubMed ID: 17243067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
    Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
    JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review.
    Feller L; Wood NH; Lemmer J
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct; 104(4):455-60. PubMed ID: 17604657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
    Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.
    De Beaudrap P; Boullé C; Lewden C; Gabillard D; Nacro B; Diagbouga S; Fassinou P; Hien H; Laurent C; Msellati P;
    Pediatr Infect Dis J; 2013 Apr; 32(4):354-60. PubMed ID: 23099424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.